Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 100,000 Shares

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $22.59, for a total transaction of $2,259,000.00. Following the transaction, the director owned 208,504 shares in the company, valued at approximately $4,710,105.36. This trade represents a 32.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Trading Up 9.9%

Shares of NASDAQ:IMNM traded up $2.12 during midday trading on Thursday, hitting $23.61. The stock had a trading volume of 1,869,014 shares, compared to its average volume of 1,683,587. The company has a market capitalization of $2.67 billion, a PE ratio of -9.92 and a beta of 2.07. Immunome, Inc. has a 1 year low of $7.96 and a 1 year high of $27.65. The stock has a 50 day moving average price of $20.96 and a two-hundred day moving average price of $21.78.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. As a group, equities analysts expect that Immunome, Inc. will post -2.06 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Stephens dropped their price objective on Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Barclays started coverage on shares of Immunome in a research report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price objective for the company. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Finally, Craig Hallum raised their target price on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Immunome currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.17.

Institutional Trading of Immunome

A number of hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its holdings in Immunome by 285.6% in the 1st quarter. Bank of America Corp DE now owns 781,607 shares of the company’s stock valued at $17,094,000 after buying an additional 578,890 shares during the period. Edgestream Partners L.P. purchased a new position in shares of Immunome during the 1st quarter worth about $1,310,000. California State Teachers Retirement System boosted its position in shares of Immunome by 66.3% in the first quarter. California State Teachers Retirement System now owns 111,444 shares of the company’s stock worth $2,437,000 after acquiring an additional 44,432 shares during the last quarter. Quantinno Capital Management LP purchased a new stake in Immunome in the first quarter valued at approximately $222,000. Finally, Aristotle Atlantic Partners LLC acquired a new position in Immunome during the first quarter worth approximately $2,734,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.